Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274623 · ClinicalTrials.gov registry record · Phase 1
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
A Phase 1 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02274623 is a Phase 1 study that has completed, run by OPKO Health. The registered enrollment target is 33 participants.
The verdict
NCT02274623, a Phase 1 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
Interventions
- DRUG CTAP101 Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02274623
The ClinicalTrials.gov registry entry for NCT02274623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTAP101 Capsules is the first listed.
NCT02274623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02274623 about?
NCT02274623 is a clinical study titled "Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid". This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
What is the current status of trial NCT02274623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2014-12. Estimated completion is 2017-03-17.
What interventions are being tested in trial NCT02274623?
The interventions under investigation include: CTAP101 Capsules (DRUG).
Who is sponsoring clinical trial NCT02274623?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.